支气管哮喘患儿应用沙丁胺醇联合氨溴特罗治疗的效果评价  

Evaluation on the effect of salbutamol combined with ambroxol in the treatment of children with bronchial asthma

作　　者：赵云姝 ZHAO Yun-shu(Shenyang First People’s Hospital,Shenyang 110000,China)

机构地区：[1]沈阳市第一人民医院,110000

出　　处：《中国现代药物应用》2021年第17期163-165,共3页Chinese Journal of Modern Drug Application

摘　　要：目的研究支气管哮喘患儿应用沙丁胺醇联合氨溴特罗治疗的效果。方法96例支气管哮喘患儿,采用随机数字表法分为循证组和常规组,各48例。常规组采用吸入用硫酸沙丁胺醇溶液雾化吸入治疗,循证组在常规组的基础上口服氨溴特罗口服溶液进行治疗。比较两组患儿治疗前后的肺功能指标[第1秒用力呼气容积占预计值的百分比(FEV1%)、第1秒用力呼气容积占用肺活量的百分比(FEV1/FVC)],圣乔治呼吸问卷(SGRQ)评分,血清细胞因子[血清基质金属蛋白酶-2(MMP-2)、降钙素原(PCT)、基质金属蛋白酶抑制剂-1(TIMP-1)]水平。结果治疗后,两组患儿的FEV1%、FEV1/FVC均高于本组治疗前,SGRQ评分低于本组治疗前,且循证组患儿的FEV1%(85.64±10.78)%、FEV1/FVC(73.60±8.10)%均高于常规组的(80.42±11.56)%、(61.51±7.06)%,SGRQ评分(42.92±5.01)分低于常规组的(54.96±4.36)分,差异具有统计学意义(P<0.05)。治疗后,两组患儿的MMP-2、PCT、TIMP-1均低于本组治疗前,且循证组患儿的MMP-2(18.02±1.43)mg/L、PCT(7.25±1.36)μg/L、TIMP-1(20.10±1.89)μmol/L均低于常规组的(25.63±1.57)mg/L、(11.60±1.23)μg/L、(25.65±2.63)μmol/L,差异具有统计学意义(P<0.05)。结论支气管哮喘患儿应用沙丁胺醇联合氨溴特罗治疗的效果较好,可改善患儿的肺功能指标、减轻炎症反应。Objective To study the effect of salbutamol combined with ambroxol in the treatment of children with bronchial asthma.Methods A total of 96 children with bronchial asthma were divided into evidence-based group and conventional group according to random numerical table,with 48 cases in each group.The conventional group was treated with aerosol inhalation of salbutamol sulfate inhalation solution,and the evidence-based group was treated with oral ambroxol hydrochloride and clenbuterol hydrochloride oral solution on the basis of the conventional group.The pulmonary function indexes[forced expiratory volume in the 1st second as a percentage of predicted value(FEV1%),forced expiratory volume in the first second/forced vital capacity(FEV1/FVC)],St.George’s Respiratory Questionnaire(SGRQ),serum cytokines[serum matrix metalloproteinase-2(MMP-2),procalcitonin(PCT)and tissue inhibitor of metalloproteinase-1(TIMP-1)]levels were compared between the two groups.Results After treatment,the FEV1%and FEV1/FVC of the two groups were higher than those of the groups before treatment,the SGRQ score was lower than that of the groups before treatment;the FEV1%(85.64±10.78)%,FEV1/FVC(73.60±8.10)%of the evidence-based group were higher than(80.42±11.56)%and(61.51±7.06)%of the conventional group,and the SGRQ score(42.92±5.01)points was lower than(54.96±4.36)points of the conventional group;all he difference was statistically significant(P<0.05).After treatment,the MMP-2,PCT and TIMP-1 of the two groups were all lower than those of the groups before treatment,and the MMP-2(18.02±1.43)mg/L,PCT(7.25±1.36)μg/L and TIMP-1(20.10±1.89)μmol/L of the evidence-based group were lower than(25.63±1.57)mg/L,(11.60±1.23)μg/L and(25.65±2.63)μmol/L of the conventional group.All the difference was statistically significant(P<0.05).Conclusion Combination of salbutamol and ambroxol has better effect on children with bronchial asthma,and it can improve the pulmonary function indexes of the children and reduce the inflammation reactions.

关 键 词：支气管哮喘 沙丁胺醇 氨溴特罗 肺功能 血清细胞因子 

分 类 号：R725.6[医药卫生—儿科]